[1. M. Yazdanian, K. Briggs, C. Jankovsky and A. Hawi, The »high solubility« definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs, Pharm. Res. 21 (2004) 293-299; DOI: 10.1023/B:PHAM.0000016242.48642.71.10.1023/B:PHAM.0000016242.48642.71]Search in Google Scholar
[2. L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. U. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M. Chen, V. H. L. Lee and A. S. Hussain, Biopharmaceutics classification system: The scientific basis for biowaiver extensions, Pharm. Res. 19 (2002) 921-925; DOI: 10.1023/A:1016473601633.10.1023/A:1016473601633]Search in Google Scholar
[3. A. V. Yadav, A. S. Shete and A. P. Dabke, Formulation and evaluation of orodispersible liquisolid compacts of aceclofenac, Ind. J. Pharm. Educ. 44 (2010) 227-235.]Search in Google Scholar
[4. Y. Javadzadeh, M. R. Siahi, S. Asnaashari and A. Nokhodchi, Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties, Acta Pharm. 57 (2007) 99-109; DOI: 10.2478/v10007-007-0008-6.10.2478/v10007-007-0008-6]Search in Google Scholar
[5. S. Nazzal and M. A. Khan, Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters, Int. J. Pharm. 315 (2006) 110-121; DOI: 10.1016/j.ijpharm.2006.02.019.10.1016/j.ijpharm.2006.02.019]Search in Google Scholar
[6. N. Rasenack and B. W. Müller, Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs, Pharm. Res. 19 (2002) 1894-1900; DOI: 10.1023/A:1021410028371.10.1023/A:1021410028371]Search in Google Scholar
[7. A. B. Nighute and S. B. Bhise, Enhancement of dissolution rate of Rifabutin by preparation of microcrystals using solvent change method, Int. J. Pharm. Tech. Res. 1 (2009) 142-148.]Search in Google Scholar
[8. G. V. Betager and K. R. Makarla, Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques, Int. J. Pharm. 126 (1995) 155-160; DOI: 10.1016/0378-5173(95) 04114-1.]Search in Google Scholar
[9. J. W. Millard, F. A. Alvarez-Núñez and S. H. Yalkowsky Solubilization by cosolvents establishing useful constants for the log-linear model, Int. J. Pharm. 245 (2002) 153-166; DOI: 10.1016/ S0378-5173(02)00334-4.10.1016/S0378-5173(02)00334-4]Search in Google Scholar
[10. P. Balakrishnan, B. Le, D. H. Oh, J. O. Kim, M. J. Hong, J. Jee, J. A. Kim, B. K. Yoo, J. S. Woo, C. S. Yong and H. Choi, Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS), Eur. J. Pharm. Biopharm. 72 (2009) 539-545; DOI: 10.1016/j. ejpb.2009.03.001.]Search in Google Scholar
[11. A. Zvonar, K. Berginc, A. Kristl and M. Ga{perlin, Microencapsulation of self-microemulsifying system: Improving solubility and permeability of furosemide, Int. J. Pharm. 388 (2010) 151-158; DOI: 10.1016/j.ijpharm.2009.12.055.10.1016/j.ijpharm.2009.12.055]Search in Google Scholar
[12. H. A. Hassan, A. H. Al-Marzouqi, B. Jobe, A. A. Hamza and G. A. Ramadan, Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with b-cyclodextrin using supercritical carbon dioxide, J. Pharmaceut. Biomed. 45 (2007) 243-250; DOI: 10.1016/j.jpba.2007.06.011.10.1016/j.jpba.2007.06.011]Search in Google Scholar
[13. T. Tanino, T. Ogiso, M. Iwaki, G. Tanabe and O. Muraoka, Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs, Int. J. Pharm. 163 (1998) 91-102; DOI: 10.1016/S0378-5173(97)00374-8.10.1016/S0378-5173(97)00374-8]Search in Google Scholar
[14. S. G. Kapsi and J. W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229(2001) 193-203; DOI: 10.1016/S0378-5173(01)00867-5.10.1016/S0378-5173(01)00867-5]Search in Google Scholar
[15. D. X. Li, Y. Oh, S. Lim, J. O. Kim, H. J. Yang, J. H. Sung, C. S. Yong and H. Choi, Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique, Int.J. Pharm. 355 (2008) 277-284; DOI: 10.1016/j.ijpharm.2007.12.020.10.1016/j.ijpharm.2007.12.020]Search in Google Scholar
[16. V. Stella, J. Haslam, N. Yata, H. Okada, S. Lindenbaum and T. Higuchi, Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule, J. Pharm. Sci. 67 (1978) 1375-1377.10.1002/jps.2600671011]Search in Google Scholar
[17. V. K. Nagabandi, T. Ramarao and K. N. Jayaveera, Liquisolid compacts: A novel approach to enhance bioavailability of poorly soluble drugs, Int. J. Pharm. Biol. Sci. 1 (2011) 89-102.]Search in Google Scholar
[18. N. Tiong and A. A. Elkordy, Effects of liquisolid formulations on dissolution of naproxen, Eur. J. Pharm. Biopharm. 73 (2009) 373-384; DOI: 10.1016/j.ejpb.2009.08.002.10.1016/j.ejpb.2009.08.002]Search in Google Scholar
[19. K. Kavitha, K. N. S. LovaRaju, N. S. Ganesh and B. Ramesh, Effect of dissolution rate by liquisolid compacts approach: An overview, Der Pharmacia Lettre 3 (2011) 71-83.]Search in Google Scholar
[20. A. S. Kulkarni, N. H. Aloorkar, M. S. Mane and J. B. Gaja, Liquisolid systems: a review, Int. J. Pharm. Sci. Nanotechnol. 3 (2010) 795-802.]Search in Google Scholar
[21. S. M. Gavali, S. S. Pacharane, S. V. Sankpal, K. R. Jadhav and V. J. Kadam, Liquisolid compact: A new technique for enhancement of drug dissolution, Int. J. Res. Pharm. Chem. 1 (2011) 705-713.]Search in Google Scholar
[22. A. B. Karmarkar, I. D. Gonjari, A. H. Hosmani, P. N. Dhabale and S. B. Bhise, Liquisolid tablets: A novel approach for drug delivery, Int. J. Health Res. 2 (2009) 45-50.]Search in Google Scholar
[23. A. B. Karmarkar, I. D. Gonjari and A. H. Hosmani, Liquisolid technology for dissolution rate enhancement or sustained release, Expert Opin. Drug Deliv. 7 (2010) 1227-1234; DOI: 10.1517/17425247.2010.511173.10.1517/17425247.2010.511173]Search in Google Scholar
[24. M. El-Hammadi and N. Awad, Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release, AAPSPharmSciTech. 13 (2012) 53-58; DOI: 10.1208/s12249-011-9719-6.10.1208/s12249-011-9719-6]Search in Google Scholar
[25. A. K. Elkhodairy and M. W. Samy, Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid systems, Lett. Drug Des. Discov. 9 (2012) 336-344; DOI: 10.2174/157018012799129873.10.2174/157018012799129873]Search in Google Scholar
[26. Y. Javadzadeh, B. Jafari-Navimipour and A. Nokhodchi, Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine), Int. J. Pharm. 341 (2007) 26-34; DOI: 10.1016/j.ijpharm.2007.03.034.10.1016/j.ijpharm.2007.03.034]Search in Google Scholar
[27. S. K. Singh, K. K. Srinivasan, K. Gowthamarajan, D. Prakash, N. B. Gaikwad and D. S. Singare, Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique, Drug Dev. Ind. Pharm. 38 (2012) 961-970; DOI: 10.3109/03639045.2011.634810.10.3109/03639045.2011.634810]Search in Google Scholar
[28. C. M. Hentzschel, A. Sakmann and C. S. Leopold, Suitability of various excipients as carrier and coating materials for liquisolid compacts, Drug Dev. Ind. Pharm. 37 (2011) 1200-1207; DOI: 10.3109/03639045.2011.564184.10.3109/03639045.2011.564184]Search in Google Scholar
[29. B. M. El-Houssieny, L. F. Wahman and N. M. Arafa, Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits, Biosci.Trends. 4 (2010) 17-24.]Search in Google Scholar
[30. K. A. Khaled, Y. A. Asiri and Y. M. El-Sayed, In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs, Int. J. Pharm. 222 (2001) 1-6; DOI: 10.1016/S0378-5173(01)00633-0.10.1016/S0378-5173(01)00633-0]Search in Google Scholar
[31. B. Chen, Z. Wang, G. Quan, X. Peng, X. Pan, R. Wang, Y. XU, G. Li and C. Wu, In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation, Int. J. Nanomed. 7 (2012) 199-209; DOI: 10.2147/IJN.S26763.10.2147/IJN.S26763]Search in Google Scholar
[32. R. H. Fahmy and M. A. Kassem, Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation, Eur. J. Pharm. Biopharm. 69(2008) 993-1003; DOI: 10.1016/j.ejpb.2008.02.017.10.1016/j.ejpb.2008.02.017]Search in Google Scholar
[33. I. D. Gonjari, A. B. Karmarkar and A. H. Hosmani, Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets, Dig. J. Nanomater. Bios. 4 (2009) 651-661.]Search in Google Scholar
[34. H. S. Mahajan, M. R. Dhamne, S. G. Gattani, A. D. Rasal and H. T. Shaikh, Enhanced dissolution rate of glipizide by a liquisolid technique, Int. J. Pharm. Sci. Nanotech. 3 (2011) 1205-1213.]Search in Google Scholar
[35. Y. Javadzadeh, L. Musaalrezaei and A. Nokhodchi, Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices, Int. J. Pharm. 362 (2008) 102-108; DOI: 10.1016/j.ijpharm.2008.06.022. 10.1016/j.ijpharm.2008.06.022]Search in Google Scholar
[36. A. Nokhodchi, R. Aliakbar, S. Desai and Y. Javadzadeh, Liquisolid compacts: The effect of cosolvent and HPMC in theophylline release, Colloid Surface B. 79 (2010) 262-269; DOI: 10.1016/j. colsurfb.2010.04.008.]Search in Google Scholar
[37. Center for the Evaluation of Risks to Human Reproduction, NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of propylene glycol, Reprod. Toxicol. 18 (2004) 533-579; DOI: 10.1016/j.reprotox.2004.01.004.10.1016/j.reprotox.2004.01.004]Search in Google Scholar
[38. Cefic, Propylene Glycol - Pharmaceuticals, n.d.; http://www.propylene-glycol.com/index.php/propylene-glycol-ups-ep-pharmaceutical-grade/pharmaceuticals, access date January 17, 2012.]Search in Google Scholar
[39. S. Gubbi and R. Jarag, Liquisolid Technique for enhancement of dissolution properties of bromhexine hydrochloride, Res. J. Pharm. Tech. 2 (2009) 382-386.]Search in Google Scholar
[40. BASF group, Lutrol® E Liquid Grades, 2010; http://www.pharma-ingredients.basf.com/Statements/Technical%20Informations/EN/Pharma%20Solutions/03_030734e_Lutrol%20E%20-%20Liquid%20Grades.pdf; access date January 18, 2012.]Search in Google Scholar
[41. R. C. Rowe, P. J. Sheskey and S. C. Owen, Handbook of Pharmaceutical Excipients, 5th ed., Pharmaceutical Press, London 2006, p. 918.]Search in Google Scholar
[42. C. F. Daher, G. M. Baroody and R. J. Howland, Effect of a surfactant, Tween 80, on the formation and secretion of chylomicrons in the rat, Food Chem. Toxicol. 41 (2003) 575-582; DOI: 10.1016/ S0278-6915(02)00299-5.10.1016/S0278-6915(02)00299-5]Search in Google Scholar
[43. T. Tatsuishi, Y. Oyama, K. Iwase, J. Y. Yamaguchi, M. Kobayashi, Y. Nishimura, A. Kanada and S. Hirama, Polysorbate 80 increases the susceptibility to oxidative stress in rat thymocytes, Toxicology 207 (2005) 7-14; DOI: 10.1016/j.tox.2004.07.020.10.1016/j.tox.2004.07.02015590117]Search in Google Scholar
[44. W. Wang, Y. J. Wang and D. Q. Wang, Dual effect of Tween 80 on protein stability, Int. J. Pharm. 347 (2008) 31-38; DOI: 10.1016/j.ijpharm.2007.06.042.10.1016/j.ijpharm.2007.06.04217692480]Search in Google Scholar
[45. S. A. Tayel, I. I. Soliman and D. Louis, Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique, Eur. J. Pharm. Biopharm. 69 (2008) 342-347; DOI: 10.1016/j.ejpb.2007.09.003.10.1016/j.ejpb.2007.09.00317949959]Search in Google Scholar
[46. M. Saeedi, J. Akbari, K. Morteza-Semnani, R. Enayati-Fard, S.Sar-Reshteh-dar and A. Soleymani, Enhancement of dissolution rate of indomethacin using liquisolid compacts, Iran J. Pharm.Res. 10 (2011) 25-34.]Search in Google Scholar
[47. V. B. Yadav and A. V. Yadav, Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique, J. Pharm. Sci. Res. 1 (2009) 44-51.]Search in Google Scholar
[48. Y. Javadzadeh, M. R. Siahi-Shadbad, M. Barzegar-Jalali and A. Nokhodchi, Enhancement of dissolution rate of piroxicam using liquisolid compacts, Il Farmaco 60 (2005) 361-365; DOI: 10. 1016/j.farmac.2004.09.005.10.1016/j.farmac.2004.09.00515848213]Search in Google Scholar
[49. A. A. Elkordy, U. Bhangale, N. Murle and M. F. Zarara, Combination of lactose (as a carrier) with Cremophor® EL (as a liquid vehicle) to enhance dissolution of griseofulvin, Powder Technol. 246 (2013) 182-186; DOI: 10.1016/j.powtec.2013.05.024.10.1016/j.powtec.2013.05.024]Search in Google Scholar
[50. B. Akinlade, A. A. Elkordy, E. A. Essa and S. Elhagar, Liquisolid systems to improve the dissolution of furosemide, Sci. Pharm. 78 (2010) 325-344; DOI: 10.3797/scipharm.0912-23.10.3797/scipharm.0912-23]Search in Google Scholar
[51. C. C. Liao and C. I. Jarowski, Dissolution rates of corticoid solutions dispersed on silicas, J. Pharm.Sci. 73 (1984) 401-403; DOI: 10.1002/jps.2600730330.10.1002/jps.2600730330]Search in Google Scholar
[52. A. A. Elkordy, X. N. Tan and E. A. Essa, Spironolactone release from liquisolid formulations prepared with CapryolTM 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles, Eur. J. Pharm. Biopharm. 83 (2013) 203-223; DOI: 10.1016/j.ejpb.2012.08.004.10.1016/j.ejpb.2012.08.004]Search in Google Scholar
[53. A. A. Elkordy, E. A. Essa, S. Dhuppad and P. Jammiqumpula, Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles, Int. J. Pharm. 434 (2012) 122-132; DOI: 10.1016/j.ijpharm.2012.05.072. 10.1016/j.ijpharm.2012.05.072]Search in Google Scholar
[54. V. Agarwal, A. Siddiqui, H. Ali and S. Nazzal, Dissolution and power flow characterization of solid self-emulsified drug delivery system (SEDDS), Int. J. Pharm. 366 (2009) 44-52; DOI: 10. 1016/j.ijpharm.2008.08.046.10.1016/j.ijpharm.2008.08.046]Search in Google Scholar
[55. G. Kahr and F. T. Madsen, Determination of the cation exchange capacity and the surface area of bentonite, illite and kaolinite by methylene blue absorption, Appl. Clay Sci. 9 (1995) 327-336; DOI: 10.1016/0169-1317(94)00028-O.10.1016/0169-1317(94)00028-O]Search in Google Scholar
[56. M. Van Speybroeck, R. Mellaerts, R. Mols, T. D. Thi, J. A. Martens, J. Van Humbeeck, P. Annaert, G. Van den Mooter and P. Augistijns, Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica, Eur. J. Pharm. Sci. 41 (2010) 623-630; DOI: 10.1016/j.ejps.2010.09.002.10.1016/j.ejps.2010.09.00220850527]Search in Google Scholar
[57. V. B. Yadav, A. B. Nighute, A. V. Yadav and S. B. Bhise, Aceclofenac size enlargement by non- -aqueous granulation with improved solubility and dissolution, Arch. Pharm. Sci. Res. 1 (2009) 115-122.]Search in Google Scholar
[58. P. G. Manogar, B. N. V. Hari and D. R. Devi, Emerging liquisolid compact technology for solubility enhancement of BCS Class-II drug, J. Pharm. Sci. Res. 3 (2011) 1604-1611.]Search in Google Scholar
[59. Fuji Chemical Industry Co., Ltd., Neusilin - Generel Properties, 2010; http://www.neusilin.com/product/general_properties.php; access date October 18, 2012.]Search in Google Scholar
[60. C. M. Hentzschel, M. Alnaief, I. Smirnova, A. Sakmann and C. S. Leopold, Tableting properties of silica aerogels and other silicates, Drug Dev. Ind. Pharm. 38 (2012) 462-467; DOI: 10.3109/03639045.2011.611806.10.3109/03639045.2011.61180621961994]Search in Google Scholar
[61. Fuji Chemical Industry Co., Ltd., Neusilin, 2011; http://www.fujichemical.co.jp/english/medical/ medicine/neusilin/index.html; access date October 18, 2012.]Search in Google Scholar
[62. Fuji Chemical Industry Co., Ltd., The Specialty Excipient Neusilin®, 2009; http://www.harke. com/fileadmin/images/pharma/Broschueren/Fuji_Neusilin.pdf; access date January 18, 2012.]Search in Google Scholar
[63. X. Zhao, Y. Q. Zhou, S. Potharaju, H. Lou, H. M. Sun, E. Brunson, H. Almoazen and J. Johnson, Development of a self micro-emulsifying tablet of cyclosporine-A by the liquisolid compact technique, Int. J. Pharm. Sci. Res. 2 (2011) 2299-2308.]Search in Google Scholar
[64. B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J. A. Martens, P. Augustijns and G. Van Den Mooter, Alternative matrix formers for nanosupension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion, Eur. J. Pharm. Sci. 35 (2008) 344-353; DOI: 10.1016/j.ejps.2008.08.003.10.1016/j.ejps.2008.08.00318765282]Search in Google Scholar
[65. M. J. Kang, S. Y. Jung, W. H. Song, J. S. Park, S. U. Choi, K. T. Oh, H. K. Choi, Y. W. Choi, J. Lee, B. J. Lee and S. C. Chi, Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets, Drug Dev. Ind. Pharm. 37 (2011) 1298-1305; DOI:10.3109/03639045.2011.571695.10.3109/03639045.2011.57169521476949]Search in Google Scholar
[66. H. Schlack, A. Bauer-Brandl, R. Schubert and D. Becker, Properties of Fujicalin®, A new modified anhydrous dibasic calcium phosphate for direct compression: Comparison with dicalcium phosphate dihydrate, Drug Dev. Ind. Pharm. 27 (2001) 789-801.10.1081/DDC-100107242]Search in Google Scholar
[67. Z. Wu, Y. Jiang, T. Kim and K. Lee, Effect of surface coating on the controlled release of vitamin B1 from mesoporous silica tablets, J. Control. Release 119 (2007) 215-221; DOI: 10.1016/j.jconrel. 2007.03.001.]Search in Google Scholar
[68. T. Ukmar and O. Planin{ek, Ordered mesoporous silicates as matrices for controlled release of drugs, Acta Pharm. 60 (2010) 373-385; DOI: 10.2478/v1007-010-0037-4.10.2478/v1007-010-0037-421169131]Search in Google Scholar
[69. M. Vallet-Regi, A. Ramila, R. P. del Rea and J. Pérez-Pariente, A new property of MCM-41: drug delivery system, Chem. Mater. 13 (2001) 308-311; DOI: 10.1021/cm0011559.70. R. Mellaerts, R. Mois, J. A. G. Jammaer, C. A. Aerts, P. Annaert, J. Van Humbeeck, G. Van den Mooter, P. Augustijns and J. A. Martens, Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica, Eur. J. Pharm. Biopharm. 69 (2008) 223-230; DOI: 10.1016/j.ejpb.2007.11.006. 10.1016/j.ejpb.2007.11.00618164930]Search in Google Scholar
[71. M. Vialpando, F. Backhuijs, J. A. Martens and G. Van den Mooter, Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds intraconazole, fenofibrate, naproxen, and ibuprofen, Eur. J. Pharm. Biopharm. 81 (2012) 190-198; DOI: 10.1016/j.ejpb.2012.01.012.10.1016/j.ejpb.2012.01.01222306694]Search in Google Scholar
[72. T. Heikkilä, J. Salonen, J. Tuura, N. Kumar, T. Salmi, D. Y. Murzin, M. S. Hamdy, G. Mul, L. Laitinen, A. M. Kaukonen, J. Hirvonen and V. P. Lehto, Evaluation of mesoporous TCPSi, MCM-41, SBA-15 and TUD-1 materials as API carriers for oral drug delivery, Drug Deliv. 14 (2007) 337-347; DOI: 10.1080/10717540601098823.10.1080/1071754060109882317701523]Search in Google Scholar
[73. M. Van Speybroeck, V. Barillaro, T. D. Thi, R. Mellaerts, J. Martens, J. Van Humbeeck, J. Vermant, P. Annaert, G. Van den Mooter and P. Augustijns, Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs, J. Pharm. Sci. 98 (2009) 2648-2658; DOI: 10.1002/jps.21638.10.1002/jps.2163819072861]Search in Google Scholar
[74. B. Chen, G. Quan, Z. Wang, J. Chen, L. Wu, Y. Xu, G. Li and C. Wu, Hollow mesoporoussilicas as a drug solution delivery system for insoluble drugs, Powder Technol. 240 (2013) 48-53; DOI: 10.1016/j.powtec.2012.07.008.10.1016/j.powtec.2012.07.008]Search in Google Scholar
[75. S. R. Gubbi and R. Jarag, Formulation and characterization of atorvastatin calcium liquisolid compacts, Asian J. Pharm. Sci. 5 (2010) 50-60.]Search in Google Scholar
[76. K. M. El-Say, A. M. Samy and M. I. Fetouh, Formulation and evaluation of rofecoxib liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 3 (2010) 135-142.]Search in Google Scholar
[77. A. Krupa, D. Majda, R. Jachowicz and W. Mozgawa, Solid-state interaction of ibuprofen and Neusilin US2, Thermochim. Acta 509 (2010) 12-17; DOI: 10.1016/j.tca.2010.05.009.10.1016/j.tca.2010.05.009]Search in Google Scholar
[78. A. Sheth and C. I. Jarowski, Use of powdered solutions to improve the dissolution rate of polythiazide tablets, Drug Dev. Ind. Pharm. 16 (1990) 769-777; DOI: 10.3109/03639049009114908.10.3109/03639049009114908]Search in Google Scholar
[79. E. B. Basalious, W. El-Sebaie and O. El-Gazayerly, Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies, Pharm. Dev. Technol. 18 (2013) 407-416; DOI: 10.3109/]Search in Google Scholar
[10837450.2012.659258.]Search in Google Scholar
[80. S. S. Spireas, C. I. Jarowski and B. D. Rohera, Powdered solution technology: Principles and mechanism, Pharm. Res. 9 (1992) 1351-1358; DOI: 10.1023/A:1015877905988.10.1023/A:1015877905988]Search in Google Scholar
[81. M. Khanfar, S. M. Sheikh and R. Hawari, Formulation factors affecting the release of ezetimibe from different liquisolid compacts, Pharm. Dev. Technol. 18 (2013) 417-427; DOI: 10.3109/10837450.2012.680594.10.3109/10837450.2012.680594]Search in Google Scholar
[82. S. Spireas and S. M. Bolton, Liquisolid Systems and Methods of Preparing Same, US 5,968,550, 19 October 1999.]Search in Google Scholar
[83. S. Spireas and S. M. Bolton SM, Liquisolid Systems and Methods of Preparing Same, US 6,423,339, 23 July 2002.]Search in Google Scholar
[84. K. Rajesh, R. Rajalakshmi, J. Umamaheswari and C. K. A. Kumar, Liquisolid technique: a novel approach to enhance solubility and bioavailability, Int. J. Biopharm. 2 (2011) 8-13.]Search in Google Scholar
[85. R.Grover, S. Spireas and C. Lau-Cam, Development of a simple spectrophotometric method for propylene glycol detection in tablets, J. Pharm. Biomed. Anal. 16 (1998) 931-938; DOI: 10.1016/ S0731-7085(97)00098-8.10.1016/S0731-7085(97)00098-8]Search in Google Scholar
[86. R. Boghra, A. Patel, H. Desai and A. Jadhav, Formulation and evaluation of irbesartan liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 9 (2011) 32-37.]Search in Google Scholar
[87. S. V. Kasture, S. B. Gondkar, A. B. Darekar, D. Priyobrata and K. V. Bhambar, Enhancement of dissolution rate of lansoprazole using liquisolid tablet technique, Int. J. Pharm. Res. 3 (2011) 27-31.]Search in Google Scholar
[88. M. A. Hassan and H. M. El-Saghir, Enhancement of dissolution and the anti-inflammatory effect of nimesulide, using liquisolid compact for oral appliccation, Bull. Pharm. Sci. 34 (2011) 1-8. 10.1248/bpb.34.1]Search in Google Scholar
[89. The European Directorate for the Quality of Medicines & Health Care, European Pharmacopoeia 7.2, 2011; http://online6.edqm.eu/ep702/; access date February 18, 2012.]Search in Google Scholar
[90. D. C. Bibby, N. M. Davies and I. G. Tucker, Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems, Int. J. Pharm. 197 (2000) 1-11; DOI: 10.1016/S0378-5173(00)00335-5.10.1016/S0378-5173(00)00335-5]Search in Google Scholar
[91. D. Q. Craig, The mechanisms of drug release from solid dispersions in water-soluble polymers, Int. J. Pharm. 231 (2002) 131-144; DOI: 10.1016/S0378-5173(01)00891-2.10.1016/S0378-5173(01)00891-2]Search in Google Scholar
[92. A. Nokhodchi, C. M. Hentzschel and C. S. Leopold, Drug release from liquisolid systems: speed it up, slow it down, Expert Opin. Drug Deliv. 8 (2011) 191-205; DOI: 10.1517/17425247.2011.548801.10.1517/17425247.2011.54880121222556]Search in Google Scholar
[93. A. Panda and D. M. Biyani, Studies on liquisolid system as a technique to modify the dissolution rate of nefedipine, Am. J. Pharmtech. Res. 3 (2013) 686-698.]Search in Google Scholar
[94. N. Chella, N. Shastri and R. R. Tadikonda, Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan, Acta Pharm. Sin B. 2 (2012) 502-508; DOI: 10.1016/j. apsb.2012.07.005..]Search in Google Scholar
[95. N. Thakur, S. L. Khokra, D. Sharma, N. S. Thakur, R. Purohit and V. Arya, A review on pharmaceutical application of liquisolid technique, Am. J. Pharmtech. Res. 1 (2011) 1-18. ]Search in Google Scholar